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Glioblastoma (GBM), the most aggressive brain tumor, is associated with a median survival
at diagnosis of 16–20 months and limited treatment options. The key hallmark of GBM is
altered tumor metabolism and marked increase in the rate of glycolysis. Aerobic glycolysis
along with elevated glucose consumption and lactate production supports rapid cell
proliferation and GBM growth. In this study, we examined the gene expression proﬁle of
metabolic targets in GBM samples from patients with lower grade glioma (LGG) and GBM.
We found that gene expression of glycolytic enzymes is up-regulated in GBM samples and
signiﬁcantly associated with an elevated risk for developing GBM. Our ﬁndings of clinical
outcomes showed that GBM patients with high expression of HK2 and PKM2 in the
glycolysis related genes and low expression of genes involved in mitochondrial
metabolism-SDHB and COX5A related to tricarboxylic acid (TCA) cycle and oxidative
phosphorylation (OXPHOS), respectively, was associated with poor patient overall survival.
Surprisingly, expression levels of genes involved in mitochondrial oxidative metabolism are
markedly increased in GBM compared to LGG but was lower compared to normal brain.
The fact that in GBM the expression levels of TCA cycle and OXPHOS-related genes are
higher than those in LGG patients suggests the metabolic shift in GBM cells when
progressing from LGG to GBM. These results are an important step forward in our
understanding of the role of metabolic reprogramming in glioma as drivers of the tumor and
could be potential prognostic targets in GBM therapies.
Keywords: glioblastoma, glucose metabolism, aerobic glycolysis, the Warburg effect, brain

INTRODUCTION
Glioblastoma Multiforme (GBM) is the most proliﬁc and deadly malignant brain tumor in the
United States with an age-adjusted incidence rate of 3.2 cases per 100,000 population and more than
13,000 cases projected in 2020 (Louis et al., 2016; Ostrom et al., 2017; Ostrom et al., 2019). The
median survival at GBM diagnosis is less than 18 months and fewer than 7% of patients exhibit longterm survival greater than 5 years (Holland, 2001; Gallego, 2015; Ostrom et al., 2017; Ostrom et al.,
2019). Currently, the treatment options for GBM include surgical resection, radiotherapy, and
temozolomide-based chemotherapy (Stupp et al., 2005; Chen et al., 2015). Despite these treatment
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availability, the median survival has only been improved from less
than 10 months in the late 1970s (Salcman, 1980; Prados et al.,
1998) to approximately 15 months (Stupp et al., 2005; Koshy
et al., 2012; Ostrom et al., 2017; Ostrom et al., 2019). However, it
remains that a more thorough understanding of GBM-centric
biology is crucial in the improving clinical outcomes for GBM
patients. Therefore, it is critical for early GBM detection and
prevention for reducing the high mortality rate. A better
understanding of the molecular basis of GBM formation and
the identiﬁcation of markers are essential for the development of
preventive therapies targeting the speciﬁc GBM-promoting
factors and thereby improve prognosis.
Recent studies have identiﬁed the role of altered cellular
metabolism as a key hallmark of GBM playing an important
role in enhancing the invasiveness of tumor cells. Metabolic
reprogramming allows invasive cells to generate the energy
necessary for colonizing surrounding brain tissue and adapt to
new microenvironments with unique nutrient and oxygen
availability. Akin to many other cancers, GBM cells exhibit the
Warburg effect, where even in the presence of high levels of
oxygen, cancer cells exhibit a strong preference for glycolysis
(Cairns et al., 2011; Koppenol et al., 2011). In GBM, glycolysis has
been suggested to correlate with tumor proliferation, invasion,
angiogenesis, and chemotherapy/radiotherapy resistance
(Kathagen-Buhmann et al., 2016; Son et al., 2020; Garcia et al.,
2021). In addition, glycolysis could shape the tumor
microenvironment (TME) and regulate immune and
inﬂammatory responses (Kesarwani et al., 2019). Also,
literature suggests a shift of cancer therapies away from
radiotherapy and towards genetic or chemical interventions.
Speciﬁcally, inhibitors with targets related to glycolysis
including hexokinase 2 (HK2) and lactate dehydrogenase A
(LDHA) are useful in selectively killing cancer cells (Galluzzi
et al., 2013). Further, recent work suggests that it is possible to
force the differentiation of glioblastoma to astrocytes by shifting
the energy preference of the GBM cells back to oxidative
phosphorylation (Xing et al., 2018). While glycolysis acts as
the dominant source of growth substrate in GBM, the role of
other metabolic from pathways including tricarboxylic acid
(TCA) cycle, oxidative phosphorylation (OXPHOS) for ATP
production and pentose phosphate pathway (PPP) which
generates the cellular reductant NADPH and macromolecules
(nucleotides, amino acids, and fatty acids) have not been
completely elucidated. There is limited data available on
altered gene expression of the enzymes involved in these
metabolic pathways in vivo. Thus, a deeper understanding of
metabolic changes including glycolysis could be an important
step towards the individualized treatment of GBM.
GBM tumors belong to a larger class of brain tumors called
gliomas, arising from glial cells. The World Health Organization
(WHO) categorizes gliomas into lower grade gliomas (LGG)
which includes grades II and III gliomas and high-grade
gliomas or GBMs, which are grade IV gliomas. GBM tumors
are known to either develop de novo or from LGG tumors. In fact,
without treatment, LGGs almost always develop into high grade
gliomas (Satar et al., 2021). Recent classiﬁcation of metabolic
properties of LGG tumors has been used to identify important
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genes in the progression of GBM from LGG, including alterations
in lipid metabolism (Wu et al., 2019) and glutamate- and
calcium-signaling (Pei et al., 2020). However, investigations
into the speciﬁc alterations in glycolysis, TCA Cycle,
OXPHOS, and PPP in LGG and GBM patients remain limited.
In this study, we investigated the expression level of enzymes
required for the glycolytic and mitochondrial metabolism in
brain samples from patients with LGG and GBM available
from two open-source data sets. We proﬁled the hallmark
gene sets in 174 samples from GBM patients with whole
mRNA expression data from REpository for Molecular BRAin
Neoplasia DaTa (REMBRANDT) database and compared with
28 normal brain tissues. We also compared genes associated with
glycolysis, TCA cycle, PPP and OXPHOS in 530 samples from
LGG with 152 samples of GBM patients from the Cancer Genome
Atlas (TCGA). Notably, the glycolysis-related risk signature could
independently identify patients in the high risk group with poor
prognosis.

MATERIALS AND METHODS
Data Sets Review
Analysis of differential gene expression in GBM tumors
compared with healthy tissues and survival comparisons
between cohorts of glioma patients were performed using
publicly available datasets available through the REpository for
Molecular BRAin Neoplasia DaTa (REMBRANDT) (Kotliarov
et al., 2006; Madhavan et al., 2009; Gusev et al., 2018). We selected
this dataset (GSE108476) due to its large size and comprehensive
information on tumor grading. This dataset was accessed through
Georgetown Database of Cancer (G-DOC ) (Bhuvaneshwar
et al., 2016) (study id: 580). This dataset includes information
on 671 patients submitted from 14 institutions between 2004 and
2006 (Gusev et al., 2018). Total RNA from each sample was
processed with the Affymetrix HG U133 V2.0 Plus gene
expression chips (Madhavan et al., 2009). From this dataset,
we extracted data on all GBM (NGBM  174) patients who had
both gene expression and survival time available, all astrocytoma
(NASTRO  116) patients who had both gene expression and
survival time available, and all healthy (NNORM  28) patients
which had gene expression data available. Gene expression was
processed with MAS5 normalization on G-DOC® and extracted
for further analysis.
Analysis of differential gene expression in GBM tumors
compared with lower grade glioma (LGG) tissues were
performed using publicly available datasets available through
The Cancer Genome Atlas (TCGA) (Brennan et al., 2013). We
selected these datasets due to their extensive normalization
procedure, RNA Seq V2 RSEM, which allows for the
comparison of relative gene expression across sample runs
(Williams et al., 2014; Li and Dewey, 2011). The TCGA-GBM
dataset (GSE83130) includes information on 543 patients with
World Health Organization (WHO) grade IV gliomas. We
extracted all GBM patients with total RNA expression
available (NTCGA-GBM  152). The TCGA-LGG dataset
includes information on 530 patients with WHO grades II or
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FIGURE 1 | Glycolytic genes are signiﬁcantly overexpressed in GBM compared with normal tissue. (A) Schematic overview of glycolysis. Abbreviations of the
enzymes are as follows: hexokinase 2 (HK2), glucose-6-phosphate isomerase (GPI), phosphofructokinase liver isoform (PFKL), aldolase A (ALDOA), glyceraldehyde 3
phosphate dehydrogenase (GAPDH), phosphoglycerate kinase 1 (PGK1), phosphoglycerate mutase 1 (PGAM), enolase 1 (ENO1), and pyruvate kinase M2 (PKM2),
lactate dehydrogenase (LDH). Abbreviations of the metabolites are as follow: glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), fructose 1,6-biphosphate
(F1,6BP), glyceraldehyde 3-phosphate (GAP), and dihydroxyacetone phosphate (DHAP), 1,3-biphosphoglycerate (1,3BPG), glycerol-3-phosphate (3-PG), glycerol-2phosphate (2-PG), phosphoenolpyruvate (PEP) (B) Relative gene expression of different glycolytic enzymes in the clinical data set GSE108476 consisting of GBM brain
tissues (n 174) and normal (n 28) brain tissues. Gene expression data from the Repository for Molecular Brain Neplasia Data (REMBRANDT) via Affymetrix HG U133
v2.0 Plus. Signiﬁcance calculated via Mann-Whitney Test. * indicates p < 0.05, ** indicates p < 0.001, **** indicates p < 0.0001, N/S indicates not signiﬁcant.

expression than the median were assigned to the ‘High
Expression’ group. Patients having lower gene expression than
the median were assigned to the ‘Low Expression’ group.
GraphPad was used to generate Kaplan Meier plots and
calculate signiﬁcance using the Log-rank (Mantel-Cox) test.
Signiﬁcance was assigned at p-value < 0.05.

III gliomas including 134 Oligoastrocytoma, 130 Anaplastic
Astrocytoma, 120 Oligodendroglioma, 78 Anaplastic
Oligoastrocytoma, 67 Astrocytoma, and 1 Diffuse Glioma
patient. We extracted all LGG patients with total RNA
expression available (NTCGA-LGG  530). Both TCGA datasets
were downloaded from the cBioPortal for Cancer Genomics
(cbioportal.org) (Cerami et al., 2012; Gao et al., 2013). Relative
RNA Seq V2 RSEM normalized gene expression data was
extracted for further analysis.

RESULTS

Data Sets Analysis

A salient feature of GBM cells is that they adjust their metabolic
proﬁle to fulﬁll the bioenergetics and anabolic demands of the
high rates of proliferation (Zhou and Wahl, 2019; Garcia et al.,
2021). Yet, little is known about the metabolic changes at stages of
the disease. To have a complete overview of the metabolic genes
expressed in LGG and GBM stages of disease, we analyzed the
transcription proﬁling of enzymes involved in glycolysis, PPP,
TCA, and OXPHOS in brain samples from patients with LGG
and GBM.

Differential gene expression between normal and GBM patients
was analyzed by downloading raw data from the REMBRANDT
study from National Center for Biotechnology Information
(NCBI) using the GSE accession number (GSE108476).
Clinical data and reporter IDs for speciﬁc genes were accessed
using Georgetown Database of Cancer (G-DOC ®) (study id: 580).
Each sample was then categorized by tumor grade, survival time,
and diagnosis. GBM, astrocytoma, and non-tumor samples were
extracted for further analysis.
Gene expression was compared between GBM patients and
healthy patients. GraphPad was used to perform a nonparametric Mann-Whitney U-test with exact p-values.
Signiﬁcance threshold was assigned at p-value < 0.05.
Relative survival within glioma patients was analyzed based on
a combined cohort of GBM (NGBM  174) and astrocytoma
(NASTRO  116) patients for a combined cohort of glioma
(NGLIOMA  290) patients. Within each gene, the glioma
cohort was separated into two groups based on the median
value of gene expression. Patients having higher gene
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Key Glycolysis-Related and PPP Gene
Expression Increases in GBM Patients
The glycolytic pathway is a well-orchestrated and characterized
series of ten enzymatic reactions converting glucose to pyruvate
(Figure 1A). We evaluated the mRNA expression levels of
these ten enzymes. These ten genes include HK2 (hexokinase
2), GPI (glucose-6-phosphate isomerase), PFK p (6phosphofructokinase), ALDOC (aldolase, fructose bisphosphate
C), GAPDH (glyceraldehyde 3-phosphate dehydrogenase), PGK1
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FIGURE 2 | Gene expression of PPP enzymes are signiﬁcantly overexpressed in GBM compared with normal tissue. (A) Schematic overview of the oxidative phase
of the pentose phosphate pathway. Abbreviations of the enzymes are as follows: glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconolactonase (PGLS),
6-phosphogluconate dehydrogenase (PGD). Activation of the two dehydrogenase enzymes, G6PD-the rate-limiting enzyme–and PGD, results in the production of
NADPH, H+ ions, and ribose 5-phosphate. (B) Relative gene expression of G6PD, PGLS, and PGD in the clinical data set GSE108476 consisting of GBM brain
tissues (n 174) and normal (n 28) brain tissues. G6PD is downregulated in cancer tissue compared with normal brain tissue. PGLS and PGD are upregulated in cancer
tissue compared with normal brain tissue. Gene expression data from the Repository for Molecular Brain Neplasia Data (REMBRANDT) via Affymetrix HG U133 v2.0 Plus.
Signiﬁcance calculated via Mann-Whitney Test. *** indicates p < 0.001, **** indicates p < 0.0001.

patients (p < 0.0001). This is interesting as LDHA enzyme
converts pyruvate into lactate generating NAD+ and diverting
glycolysis-derived pyruvate from the mitochondrial oxidative
pathway (Hay, 2016). In contrast, mRNA expression of PFKL
(p  0.62), ENO1 (p  0.46), and PKM1/2 (p  0.17) showed no
signiﬁcant changes.
We also examined the relative gene expression of enzymes
involved in the oxidative phase of PPP. PPP branches from
glucose 6-phosphate (G6P), produces NADPH and ribose 5phosphate (R5P), and shunts carbons back to the glycolytic or
gluconeogenic pathway (Figure 2A). We found that two of PPP
genes,
6-phosphogluconolactonase
(PGLS)
and
6phosphogluconate dehydrogenase (PGD) were signiﬁcantly
upregulated (p < 0.0001) in GBM patients compared to
healthy patients while expression of glucose 6-phosphate
dehydrogenase (G6PD) was found to be signiﬁcantly
downregulated (p < 0.001) in GBM patients than in healthy
patients (Figure 2B). The decrease in the expression of G6PD,
which is the rate limiting enzyme for PPP, indicates that glucose
metabolism may be shifting away from PPP to neuronal glycolysis
leading to higher susceptibility to oxidative stress in the brain.
Additional oxidative stress in the GBM brain could contribute to
poor patient prognosis. The increase in PGLS and PGD indicates
that the production of R5P required for nucleotide synthesis
during cell growth and NADPH production for energy
requirements. Together, these results imply an overall increase

(phosphoglycerate kinase 1), PGAM1 (phosphoglycerate mutase
1), ENO1 (enolase 1), PKM1/2 (pyruvate kinase M1/2), and
LDHA (lactate dehydrogenase A). As shown in Figure 1B,
expression of the rate limiting glycolytic transcript, HK2 (p <
0.0001), was signiﬁcantly increased in GBM patients compared to
normal patients. The HK2 overexpression has been shown to
contribute to the enhanced glycolytic rate and tumor progression
and confer resistance to apoptosis to cancer cells (Vartanian et al.,
2016). Along with this, a majority of glycolytic transcripts
including ALDOC (p < 0.0001), GAPDH (p < 0.001), PGK1
(p < 0.05), and PGAM1 (p < 0.0001), were signiﬁcantly
increased in GBM patients compared to normal patients.
ALDOC is speciﬁc to the brain region and is involved in the
fructolysis process which is shown to promote the Warburg effect
by preferentially downregulating OXPHOS and mitochondrial
respiration and increase aerobic glycolysis that may aid
metastases that initially have low oxygen supply (KathagenBuhmann et al., 2016; Nakagawa et al., 2020). GAPDH has
been shown to enhance mitophagy and induce cancer cell
survival (Zhang et al., 2015). High expression of PGK1 is
correlated with tumor proliferation, metastasis, occurrence,
development and prognosis prediction (Ding et al., 2014; Fu
and Yu, 2020). Overexpression of PGAM1 is linked with tumor
growth, survival, and invasion in several cancers including GBM
(Zhang et al., 2017; Liu et al., 2018). Expression of LDHA and GPI
was signiﬁcantly reduced in GBM samples compared to normal
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FIGURE 3 | Analysis of gene expression of oxidative mitochondrial metabolism. (A) Relative gene expression of PDH1, IDH2, and SDHB implicated in the TCA cycle
in the clinical data set GSE108476 consisting of GBM brain tissues (n 174) and normal (n 28) brain tissues. PDH1, IDH2, and SDHB gene expression is signiﬁcantly
under expressed in GBM tissue compared with normal tissue. (B) Relative gene expression of UQCRB, COX5A, and NDUFA5 implicated in oxidative phosphorylation in
the clinical data set GSE108476 consisting of GBM brain tissues (n 174) and normal (n 28) brain tissues. UQCRB, COX5A, and NDUFA5 are signiﬁcantly under
expressed in GBM tissue when compared to normal tissue. Gene expression data from the Repository for Molecular Brain Neplasia Data (REMBRANDT) via Affymetrix
HG U133 v2.0 Plus. Signiﬁcance calculated via Mann-Whitney Test. *** indicates p < 0.001, **** indicates p < 0.0001.

in glycolytic and PPP genes driving the production of excess ATP
and nucleotides which give way to unchecked proliferation in
GBM cells.

reactions (Guzy et al., 2008). Lack of SDHB has been shown to
impair mitochondrial oxygen consumption and commit cells to
ferment glucose for sustaining their energetic needs (LusseyLepoutre et al., 2015). The lack of SDH in GBM cells possibly
results in a complete deﬁciency of the enzyme activity and
abnormal accumulation of succinate in GBM. Isocitrate
dehydrogenases 2 (IDH2) catalyzes isocitrate to alphaketoglutarate and generates NADPH in the TCA cycle. Loss of
IDH2 has been shown to impair oxidative bioenergetics, elevate
reactive oxygen species (ROS) production, and promote
exaggerated mitochondrial dynamics in prostate cancer cells
(Wang et al., 2019). Our observations are consistent with
numerous studies showing that decreased levels of the TCA
associated genes in GBM promotes the Warburg effect and
tumor growth.

Gene Expression of Enzymes of TCA Cycle
Decreases in GBM Patients
While normal cells utilize glucose as the main source of pyruvate
entering the TCA cycle, tumor cells often shunt glucose away
from the TCA cycle for catabolism through anaerobic glycolysis.
Also, inherited and acquired alteration of TCA cycle enzymes
have been demonstrated in different cancers (Pavlova and
Thompson, 2016; Anderson et al., 2018). We examined the
gene expression levels of three key metabolic enzyme of TCA
cycle: pyruvate dehydrogenase E1 alpha 1 subunit (PDHA1),
isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2),
and succinate dehydrogenase (SDHB). We observed that all three
genes were signiﬁcantly lower than that in normal patients (p <
0.0001) (Figure 3A). Loss of PDHA1 has been shown to decrease
mitochondrial OXPHOS and promote aerobic glycolysis in
tumor cells and promotes Warburg effect (Liu et al., 2015; Sun
et al., 2019). SDH catalyzes the oxidation of succinate to fumarate
in the TCA cycle while simultaneously reducing ubiquinone to
ubiquinol in the mitochondrial electron transport chain (ETC)
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Gene Expression of Enzymes of
Mitochondrial Oxidative Metabolism
Decreases in GBM Patients
The regulation of the TCA cycle is cued in with its constant
feedback with OXPHOS is critical for metabolic activities in
normal cells. In contrast, in tumor cells glycolysis is enhanced
and OXPHOS capacity is reduced in tumor cells (Zheng, 2012;
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FIGURE 4 | Changes in gene metabolic gene expression is associated with poor patient prognosis. Shown are the Kaplan-Meier overall survival curves of GBM
patients according to the designated gene expression levels above or below the median value based. (A) High expression of glycolysis related genes, HK2 and PKM2,
correlated with poor overall GBM patient’s survival. There was no signiﬁcant difference in survival based on PFKL or LDHA expression. (B) Low expression of PPP related
genes, G6PD and PGLS, correlated with poor overall GBM patient’s survival. There was no signiﬁcant difference in survival based on PGD expression. (C) Low
(Continued )
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FIGURE 4 | expression of TCA related gene, SDHB, correlated with poor overall GBM patient’s survival. There was no signiﬁcant difference in survival based on PDHA1
or PGD expression. (D) Low expression of OXPHOS related gene, COX5A, correlated with poor overall GBM patient’s survival. There was no signiﬁcant difference in
survival based on UQCRB or NDUFA5 expression. Gene expression in GBM tumors and associated patient survival from the REpository for Molecular BRAin Neoplasia
®
DaTa (REMBRANDT) (GSE108476) via Affymetrix HG U133 V2.0 Plus gene expression chips. Gene expression was processed with MAS5 normalization on G-DOC
before comparison. Signiﬁcance calculated via Log-rank (Mantel-Cox) test. Low expression, n  145. High expression, n  145. Exact p-values reported.

Duan et al., 2018). To test whether this was the case for GBM, we
analyzed the expression proﬁle of representative genes involved
in the formation of the electron transport chain complexes:
NADH: Ubiquinone Oxidoreductase Subunit A5 (NDUFA5
-complex I); Ubiquinol-Cytochrome C Reductase Binding
Protein (UQCRB-complex III), Cytochrome C Oxidase Subunit
5A (COX5A-complex IV). As shown in Figure 3B, all three genes
were signiﬁcantly reduced (p < 0.0001) in GBM patients
compared with healthy patients. This corroborates with the
changes observed in glycolysis and TCA cycle genes.
Altogether, these results indicate that in GBM patients the
expression of glycolytic related genes is higher relative to normal
brain, while the expression of TCA cycle and OXPHOS genes are
reduced compared to normal brain (Figures 1–3). Importantly,
Niclou and colleagues have investigated the importance of
glycolytic enzymes in GBM adaption and survival including
HK2, ALDO, and PGAM1 in 5 patient-derived GBM stem-like
cell lines and found that inhibition of these glycolytic genes
pathway strongly affects GBM growth in patient-derived
intracranial mouse models (Sanzey et al., 2015). This
comprehensive study on glycolytic enzymes are in agreement
line with our analyses whereby changes in transcript expression of
glycolysis, TCA cycle and OXPHOS, in GBM are consistent with
a Warburg-type metabolism.

that patients’ gene expression proﬁles could be correlated with
overall clinical outcome. In particular, patients with higher
expression of glycolytically related genes have poor prognosis
and survival rates indicating a potential route for therapeutic
development.
Gene Expression of Enzymes Involved in Glycolysis, TCA
Cycle, Mitochondrial Oxidative Metabolism, and PPP is Higher
in GBM compared with LGG
Brain lower-grade and intermediate-grade glioma (LGGclassiﬁed as grade I, II, or III) are inﬁltrative neoplasms that has
highly variable clinical behavior but often poor prognosis (Brat
Daniel et al., 2015). While phenotypically less aggressive than GBM,
LGGs represent a disease in need of further exploration to advance
treatment options and prolong patient survival. To better
understand the metabolic alterations in LGGs in comparison to
GBMs, we examined the expression of glycolytic transcripts and
transcripts of PPP, TCA cycle and OXPHOS in a clinical data set
with 152 GBM and 530 LGG patients from the TCGA database
(Figure 5). Compared with LGG, GBM tumors expressed higher
levels of LDHA (8.1 fold) and genes involved in glucose uptake
including HK2, PFKL, and PKM (3.7, 2.1, 2.9 fold) (Figure 5A).
Interestingly, all ten glycolytic related genes were signiﬁcantly higher
expression in GBM compared to LGG samples (p < 0.0001). Indeed,
a WHO tumor-grade dependent change in glycolytic enzymes have
been previously reported. Liu and colleagues have demonstrated a
tumor-grade dependent increase in HK2 protein expression (Liu
et al., 2017), whereas Mukherjee and colleagues have demonstrated a
tumor-grade dependent increase in PKM2 gene expression
(Mukherjee et al., 2013). Together, these further support a
transition towards glycolysis as tumor grades increase from LGG
to GBM. Also, GBM tumors exhibited elevated expression of PPP
genes including G6PD, PGLS, and PGD (p < 0.0001) (Figure 5B). In
addition, GBM tumors expressed higher levels of TCA cycle genes
including IDH2 (the primary producer of NADPH in GBM) (Wahl
et al., 2017) compared to LGG (Figure 5C). The GBM-activated PPP
also generate NADPH, which is a reducing equivalent for tumor cells
affected by the Warburg effect (Liberti and Locasale, 2016).
Interestingly, LDHA was the highest fold change in GBM
compared to LGG indicating that the conversion of pyruvate to
lactate and Warburg related properties were exacerbated during the
tumor shift. Together, these results suggest that GBM tumors
metabolically rely on the Warburg effect.
Similarly, we evaluated the transcripts levels of representative
OXPHOS genes- UQCRB, COX5A, and NDUFA5- in LGG and
GBM patients. The expression of OXPHOS-related genes were
signiﬁcantly higher in GBM compared to LGG (p < 0.0001)
(Figure 5D). This result suggest that, in contrast to a general
increase in glycolysis genes, TCA and OXPHOS genes remained
higher in GBM. Compared to normal patients, GBM patients
expressed lower levels of genes involved in TCA cycle and

Expression of Glycolytic Genes Correlates
With Poor Patient Survival in GBM
We next investigated the survival correlation of GBM patients
with key regulators of aerobic glycolysis and mitochondrial
metabolism using the REMBRANDT dataset (GSE108476).
This data was analyzed via Kaplan-Meier plots and
signiﬁcance was determined with a Log-rank (Mantel-Cox)
test (Figure 4). In two rate limiting steps of glycolysis, the
overall survival rate was signiﬁcantly lower in high expression
of HK2 (p  0.0017) and PKM2 (p  0.0079) (Figure 4A). There
was not a signiﬁcant correlation found within the two remaining
rate limiting enzymes, PFKL and LDHA. Interestingly, the
opposite trend was noted within the expression of genes
associated with the PPP. Low expression of G6PD (p  0.0196)
and PGLS (p  0.0494) was correlated with worse patient
outcomes (Figure 4B). There was no signiﬁcant difference in
the survival of patients with PGB gene expression. In the TCA
cycle-related genes, lower expression of SDHB (p < 0.0001)
correlated to worse patient outcomes while PDHA1 and PGD
displayed no signiﬁcant difference in survival (Figure 4C).
Finally, in the OXPHOS genes, we found a signiﬁcant
correlation with lower expression of COX5A (p < 0.0001) and
poor clinical outcomes, while UQCRB and NDUFA5 showed no
signiﬁcant correlation (Figure 4D). Taken together, this indicates
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FIGURE 5 | Metabolic gene expression higher in glioblastoma (GBM) patients than in LGG patients. (A) Higher glycolytic gene expression in glioblastoma (GBM)
patients compared with lower grade glioma (LGG) patients. Red RL indicates association with a rate limiting step of glycolysis. (B) Higher relative gene expression of TCA
cycle genes in glioblastoma (GBM) patients compared with lower grade glioma (LGG) patients.(C) Higher relative gene expression of PPP genes in glioblastoma patients
compared with lower grade glioma (LGG) patients.(D) Higher relative gene expression of oxidative phosphorylation (OXPHOS) genes expression in glioblastoma
(GBM) patients compared with lower grade glioma (LGG) patients. Gene expression data from The Cancer Genome Atlas (TCGA) including TCGA-LGG and TCGA-GBM
(GSE83130) downloaded from the cBioPortal for Cancer Genomics. Relative RNA Seq V2 RSEM normalized gene expression was used for analysis. Signiﬁcance
calculated via Mann-Whitney U Test. LGG n  530, GBM n  152 **** indicates p < 0.0001.

OXPHOS, but at signiﬁcantly higher levels than those found in
LGG (Figures 5C,D). This indicates that GBM tumors generate
ATP via OXPHOS as well compared to LGG under aerobic
conditions. Together, these results suggest that LGG tumors
metabolically rely primarily on the Warburg effect while GBM
utilizes TCA cycle and OXPHOS as well for their high energy
demand.

Fu and Yu, 2020). The decreased expression and activity of LDHA in
GBM over normal patients would favor the routing of pyruvate into
mitochondria where it can be further metabolized through TCA and
oxidative phosphorylation. Further, as GPI catalyzes G6P to F6P, a
decrease in GPI will interrupt the glycolytic ﬂux by increasing the
intracellular G6P pool, however it also could reactivate PPP for the
cells’ energy needs. In general, the Warburg effect drives the
biosynthesis of nucleotides, lipids, and proteins to support rapid
cell proliferation, as well as the disruption of tissue architecture to
facilitate tumor motility (Liberti and Locasale, 2016). NADPH is a
key component in this process, thus the elevated PPP, in GBM
tumors provide additional support implying a pathogenic role of
glucose metabolism for this disease.
Although, it is now well accepted that the aerobic glycolytic
phenotype is associated with an impaired mitochondrial oxidative
metabolism (Lunt and Vander Heiden, 2011), recent studies have
indicated a new paradigm that both glycolytic and mitochondrial
metabolism are used by cancer cells for ATP production and
macromolecule synthesis (Weinberg et al., 2010; Ahn and au,
2015; Gentric et al., 2017). In concordance with these studies, our
analysis in GBM patients show high expression levels of genes
related to mitochondrial metabolism compared to LGG patients.
The fact that in GBM the expression levels of TCA and OXPHOS
genes are higher than those in LGG patients suggests the metabolic

DISCUSSION
This study represents a genomic analysis to delineate the metabolic
foundations of GBM and conclude that the genetic changes in the
glycolytic genes was more reﬂective of the disease aggressiveness and
prognosis. Speciﬁcally, we report that the changes in transcript
expression of glycolysis and PPP genes in GBM is consistent
with a Warburg-type metabolism and show a positive correlation
between glycolytic gene expression and the risk of developing GBM
and poor patient survival (Figure 6). We found that the metabolic
trends in GBM varies signiﬁcantly from LGG especially with
OXPHOS and TCA cycle related genes. GBM tumors displayed
distinct Warburg-like genetic features, with increased HK2, PGAM1,
ALDOC, and PGK1 expression that facilitates lactate production and
confers resistance to hypoxic stress in cancer cells (Patra et al., 2013;
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FIGURE 6 | Summary of metabolic changes in GBM. A simpliﬁed model showing gene changes of metabolic enzymes during the progression of GBM. One of the
most pronounced transcriptional changes during the progression of GBM is the increase in genes associated with rate limiting enzymes in glycolysis including HK2,
ALDOC, GAPDH, PGK1 and PGAM1. This allows glucose to enter in the cells and be converted to pyruvate. The PPP-associated genes are upregulated as well
suggesting the entrance into oxidative phase of PPP. Surprisingly, the genes associated with TCA cycle and OXPHOS are downregulated in GBM which suggests
that GBM primarily relies on glycolysis for its energy needs. Figure was created using Biorender.

shift in GBM cells when progressing from LGG to GBM. GBM have
high expression of HK2, ALDOC, GAPDH, PGK1, and PGAM1 as
well as display a signiﬁcant increase in PGLS and PGD expression
while low expression of TCA cycle and OXPHOS related genes
compared to healthy patients. It appears that metabolic
readjustments (that is, glycolysis shift) occurs when the transition
from LGG to GBM occurs as genes related to glycolysis, PPP, TCA
cycle and OXPHOS are higher in GBM compared to LGG. Overall,
these results begs the need to evaluate the differential signature of
these metabolic regulators in normal, LGG and GBM patients and
delineate the metabolic transition especially from the less aggressive
LGG to GBM state. Further studies such as protein expression
analysis are therefore required to understand the speciﬁc
mechanisms underlying the metabolic changes observed in LGG
and GBM, although it might be difﬁcult due to shortage of human
GBM samples available.
Our analysis of clinical outcomes showed that GBM patients with
high expression of HK2 and PKM2 in the glycolysis related genes
had shorter overall survival providing the evidence that HK2 and
PKM2 constitutes important targets for GBM therapy. Knockdown
of HK2 gene has been shown to strongly inhibit GBM growth
indicating that HK2 is essential for GBM growth and also impact
overall survival (Wolf et al., 2011a; Wolf et al., 2011b). The switch in
splice isoforms from the adult pyruvate kinase muscle 1 (PKM1) to
the fetal PKM2 has been attributed to promote aerobic glycolysis and
tumor growth in lung cancer cell lines (Christofk et al., 2008;
Anastasiou et al., 2012). Interestingly, the low expression of two
metabolic genes involved in mitochondrial metabolism-SDHB and
COX5A related to TCA cycle and OXPHOS, respectively, was
associated with poor patient overall survival which parallels their
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signiﬁcant decreases in GBM samples compared to normal brain.
Succinate dehydrogenase (SDHB, also known as mitochondrial
respiratory chain complex II) is a key respiratory enzyme located
on the inner mitochondrial membrane, which links the TCA cycle
with OXPHOS and plays the important roles in both TCA cycle and
OXPHOS (Rustin et al., 2002). The low expression of SDHB has been
shown to promote aerobic glycolysis (Tseng et al., 2018), and the lack
of SDHB function has been implicated in the occurrence and
development of multiple kinds of tumors, including liver cancer,
renal cancer and colorectal cancer (Tseng et al., 2018; Rahn et al.,
2019). COX5A, one of the three mitochondrial-encoded subunit of
COX, is the terminal enzyme of the respiratory chain and key
regulator of OXPHOS (Bai et al., 2020). It has been shown that HK2
inhibits OXPHOS and promotes tumor proliferation (Wolf et al.,
2011b). Our survival data implies that the overall survival is poor in
GBM patients where aerobic glycolysis occurs along with active
suppression of OXPHOS. Prevention of GBM is an unmet medical
need and current clinical interventions do not extent the survival rate
beyond 15 months. Interestingly, our data suggests that high
expression levels of HK2, and PKM2 appear to have important
clinical implication for patients with GBM and in agreement with
studies demonstrating that inhibition of glycolysis improves survival
in GBM (McKelvey et al., 2021). By contrast, low gene expression of
SDHB (TCA cycle) and COX5A (OXPHOS) was associated with an
increased risk of GBM. This suggests that expression of these
glycolytic and metabolic enzymes could be used as a new
biomarker for the risk of developing GBM.
Altered metabolic pathways are one of the hallmarks of cancerous
cells including GBM. While plethora of studies have attributed
numerous pathways that enhance the tumor cells invasiveness in
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the brain microenvironment as the primary driving forces behind
GBM, recent studies have identiﬁed a role for cellular metabolism
reprogramming in GBM invasion. Metabolic reprogramming acts as
the energy source necessary for invasive cells to colonize
surrounding brain tissue and adapt to new microenvironments
with unique nutrient and oxygen availability. Historically,
enhanced glycolysis, even in the presence of oxygen (the
Warburg effect) has dominated GBM research with respect to
tumor metabolism. While this study allowed us to dive slightly
deeper into metabolic pathways beyond glycolysis associated with
these metabolic changes, it is important to note that glycolysis and
mitochondrial metabolism likely mark merely two of the dozens of
pathways affected during the process of GBM progression. Also of
note, alterations in each of these metabolic pathways can cause
changes in any number of downstream pathways. In particular, as
high levels of ROS generated from OXPHOS can cause cellular
damage, there could be alterations in the downstream antioxidant
response pathway in GBM tumors. Additionally, emerging research
suggests that amino acid metabolism, particularly glutamine
metabolism, plays an important role in the progression of cancers
(Kodama et al., 2020). As glutamine is a precursor of glutamate and
glutamate signaling plays an important role in the progression of
GBM, glutamine metabolism could therefore play a signiﬁcant role
in GBM (Pei et al., 2020). Indeed, the analysis of such downstream
pathways could offer additional insight into glioma progression.
There are also several limitations to our study. First, the
clinical tumor samples analyzed in our study were limited to
those of REMBRANDT and TCGA. This is due to the small
amount of public LGG datasets that span multiple the multiple
modalities necessary for our study (eg, RNA-seq, clinical/
survival). To this end, it may be interesting to explore whether
glycolytic and mitochondrial oxidative metabolism gene
expression correlates with patient overall survival based on
different phases and mutations of LGG and GBM in a larger
multimodal dataset. Second, while our results revealed
consistently robust statistical associations, they do not imply a
direct cause and effect relationship between LGG progression to
GBM, glycolysis, and metabolism expression. Nevertheless, as
shown in the work of Niclou and colleagues, the direct effect of
key glycolytic enzymes revealed results corroborating with our in
silico analysis (Sanzey et al., 2015). Furthermore, although the
purpose of our study was to identify clinically associated genomic
changes in glycolysis and metabolic genes in human GBM, our
results extend previous in vitro and in vivo ﬁndings to show
relevance in human tumor data. This may therefore encourage
mechanistic exploration of metabolic genes in glycolysis, PPP,

TCA cycle and OXPHOS induced changes in tumor
aggressiveness and invasiveness contributing to patient survival
outcomes. To this end, recent global proﬁling experiments have
identiﬁed roles for lipid, amino acid, and nucleotide metabolism
in tumor growth and invasion (Prabhu et al., 2019; Garcia et al.,
2021). A thorough understanding of the metabolic traits that
deﬁne invasive GBM cells may lead to novel therapeutic targets
for this devastating disease.
In summary, our analysis has expanded our knowledge of
the glioma metabolic alteration landscape, emphasized the
relevance of metabolic changes particularly glycolysisrelated genes as a modality for clinical outcomes and
survival prediction of GBM patients. Combined, these
ﬁndings are an important step forward in our
understanding of the role of metabolic reprogramming in
glioma as drivers of the tumor and could be potential
prognostic targets in GBM therapies. Our ﬁndings may
provide novel insights for GBM research and guidance for
individual therapy.
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